Skip to content

Endovascular Treatment and RIPC in Acute Ischemic Stroke

Endovascular Treatment Combined With Remote Ischemic Postconditioning in Patients With Acute Ischemic Stroke Improves the Prognosis,a Multicenter, Randomized, Prospective Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04581759
Acronym
EnTRIPS
Enrollment
300
Registered
2020-10-09
Start date
2021-04-12
Completion date
2023-10-30
Last updated
2022-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke, Endovascular Treatment

Brief summary

Endovascular treatment(ET)is an effective therapy for acute ischemic stroke(AIS) with great vessel obstruction. However, acute complications such as high postoperative perfusion injury, hemorrhagic transformation and restenosis resulted in functional independence in only about 50% of patients 90 days after interventional surgery. Therefore, it is very important to protect the neurologic function after emergency endovascular treatment. The investigators' previous studies have shown that combined with intravenous thrombolytic therapy and remote postconditioning(RIPC)can significantly improve the neurological impairment and short-term and long-term prognosis in patients with acute stroke. In this multicenter, randomized controlled trial, the investigators assumed patients with acute ischemic stroke who had successfully revascularization after ET might benefit from RIPC as well. Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after ET. The primary endpoint measure was the proportion of patients with a favorable recovery of nerve function deficient assessed by Modified Rankin Scale (mRS≤2) 90 days after surgery. Secondary endpoints included the following: (1) Symptom endpoints: Neurological intelligence and function scores, postoperative hemorrhagic transformation rate, etc. (2) Blood index test: postoperative inflammatory factors, neuron-specific enolase (NSE) and other indicators. (3) Imaging endpoints: MRI-FLAIR , TCD, etc.

Interventions

Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.

DRUGfoundational treatment

foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs

Sponsors

Second Affiliated Hospital of Xi'an Jiaotong University
CollaboratorOTHER
Shaanxi Provincial People's Hospital
CollaboratorOTHER
Xijing Hospital
CollaboratorOTHER
Tang-Du Hospital
CollaboratorOTHER
Xi'an No.3 Hospital
CollaboratorOTHER_GOV
Xi'an Gaoxin Hospital
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. acute ischemic stroke(AIS) patients with large vessel occlusion (internal carotid artery system and vertebral basilar artery system) within 24 hours after onset, endovascular treatment (mechanical thrombotomy, intra-arterial thrombolysis, balloon dilatation or stent angioplastyand) successful opening were performed, and the definition of successful opening was defined by Modified Thrombolysis standard \[Modified Thrombolysis in Cerebral infarction, mTICI\]≥ 2B,The standards of endovascular interventional treatment are in line with the indications and contraindications formulated in the Chinese Guidelines for the Early Treatment of Acute Ischemic Stroke 2018; 2. Modified Rankin scale score (mRS) ≤1 before onset: 3. The Alberta Stroke Program Early CT score (ASPECTS)≥6 on admission; 4. National Institute of Health Stroke Scale (NIHSS) score ≥6 on admission; 5. Provision of written informed consent.

Exclusion criteria

1. CT or MRI scan showed significant midline deviation and the mass effect; 2. Glasgow(GCS) score ≤8 on admission; 3. failure to accomplish 3-months and 6-months follow up; 4. Severe cardiac, liver, or kidney disease, malignancy, severe coagulation dysfunction, severe anemia and systemic organ dysfunction; 5. Pregnant or nursing women, or patients with moderate to severe mental disorders or dementia; 6. Severe soft tissue injuries, fractures, thrombosis and other known peripheral vascular lesions of the upper limbs,active visceral hemorrhage, acute stage of fundus hemorrhage, cerebral aneurysm or cerebral arteriovenous malformation, and other unsuitable for bilateral upper arm compression.

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin scale (mRS)7days, 90 days and 180 days after the surgery and at dischargeThe percentage of patients with a favorable outcome from baseline at 90 days and 180 days postoperatively, defined as a score of 0 or 2 on the modified Rankin scale (mRS)(Notes:mRS score from 0-6, higher scores mean worse outcome)

Secondary

MeasureTime frameDescription
The change of Barthel Index7days, 90 days and 180 days after the surgery and at dischargeThe change of functional recovery from baseline at 90 days and 180 days postoperatively, as measured by the Barthel Index (Notes:Barthel Index score from 0-100. higher scores mean better outcome)
The change of Montreal Cognitive Assessment (MoCA) score7days, 90 days and 180 days after the surgery and at dischargeThe change of cognitive recovery from baseline at 90 days and 180 days postoperatively, as measured by the MoCA (Notes:MoCA score from 0-30. higher scores mean better outcome)
The change of MMSE score7days, 90 days and 180 days after the surgery and at dischargeThe change of cognitive recovery from baseline at 90 days and 180 days postoperatively, as measured by the MMSE(Notes:MMSE score from 0-30. higher scores mean better outcome)
The change of inflammatory indicatorsbefore ET, 24 hours and 7 days after the surgeryPeripheral venous blood was drawn before Endovascular Treatment(ET) and 24 hours and 7 days postoperatively to determine the effect of repeated RIPC on anti-inflammatory (hIL-1β、hIL-2R、hIL-6、hIL8、hIL-10、S100-β、TNF-α) (Notes: unit ng/ml)
The change of angiogenic factorsbefore ET, 24 hours and 7 days after the surgeryPeripheral venous blood was drawn before ET and 24 hours and 7 days postoperatively to determine the effect of repeated RIPC on vascular (VEGF、bFGF、EPO、HIF-1α、BDNF) and other pathways (S100B、NSE)(Notes: unit ng/ml)
The change of hemoglobin and Blood viscosityup to 7 days after the surgeryPeripheral venous blood was drawn before ET and 24 hours and 7 days postoperatively to determine the effect of repeated RIPC on Hb and Blood viscosity(Notes: unit g/L , mPa.s)
Postoperative hemorrhagic transformation72 hours after ET and hospitalizationThe proportion of patients with postoperative hemorrhagic transformation, based on CT scan and symptom
The change of NIHSS score7days, 90 days and 180 days after the surgery and at dischargeThe percentage of functional recovery from baseline at 90 days and 180 days postoperatively, as measured by the National Institute of Health Stroke Scale, short for NIHSS(Notes:NIHSS score from 0-42. higher scores mean worse outcome)
The change of blood flow velocitythe changs from 24 hours after ET to 7 days after the surgeryVascular blood flow velocity measured by transcranial doppler (TCD) examination
Vascular resistancethe changs from 24 hours after ET to 7 days after the surgeryVascular resistance measured by TCD examination
mortality rateup to 90 days and 180 days90-days and 180-days mortality rate
recurrence rate of cerebrovascular diseaseup to 90 days and 180 days90-days and 180-days recurrence rate of cerebrovascular disease
blood pressureup to 7daysThe effect of RIPC on blood pressure
heart rateup to 7daysThe effect of RIPC on heart rate
The change of MRI FLAIR Fazekas scorethe changs from within 7 days to 90 days after the surgeryCerebral white matter demyelination measured by MRI FLAIR Fazekas score,(Notes:Fazekas score from 0-6. higher scores mean worse outcome)

Countries

China

Contacts

Primary ContactGuogang Luo, MD
lguogang@163.com0086-13991974085
Backup ContactMeng Wei, MD
67183723@qq.com0086-15991748135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026